skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Ranolazine (Code C66507)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Ranolazine

Definition: An orally available, piperazine derivative with anti-anginal and potential antineoplastic activities. Ranolazine's mechanism of action for its anti-ischemic effects has yet to be fully elucidated but may involve the alteration of the trans-cellular late sodium current in the ischemic myocyte. By preventing the rise of intracellular sodium levels, ranolazine may affect the transport activity of sodium-dependent calcium channels and prevent the calcium overload during myocardial ischemia, thereby preventing cellular injury. Ranolazine's potential antineoplastic effect may depend on its inhibitory effect on fatty acid oxidation, which may sensitize tumor cells to apoptosis and decrease tumor cell proliferation; fatty acid oxidation provides energy and promotes tumor cell proliferation and survival.

Display Name: Ranolazine

Label: Ranolazine

NCI Thesaurus Code: C66507 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C0073633  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
1-Piperazineacetamide, N-(2,6-dimethylphenyl)-4-(2-hydroxy- 3-(2-methoxyphenoxy)propyl)-

External Source Codes: 
CAS Registry Number 95635-55-5 (see NLM ChemIDplus info)
PDQ Closed Trial Search ID 753754
PDQ Open Trial Search ID 753754 (check for NCI PDQ open clinical trial info)
UMLS CUI C0073633

Other Properties:
     Name Value (qualifiers indented underneath)
Chemical_Formula C24H33N3O4
code C66507
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name Ranolazine
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom